Nanoparticle-based targeted gene therapy for lung cancer.
Despite striking insights on lung cancer progression, and cutting-edge therapeutic approaches the survival of patients with lung cancer, remains poor. In recent years, targeted gene therapy with nanoparticles is one of the most rapidly evolving and extensive areas of research for lung cancer. The major goal of targeted gene therapy is to bring forward a safe and efficient treatment to cancer patients via specifically targeting and deterring cancer cells in the body. To achieve high therapeutic efficacy of gene delivery, various carriers have been engineered and developed to provide protection to the genetic materials and efficient delivery to targeted cancer cells. Nanoparticles play an important role in the area of drug delivery and have been widely applied in cancer treatments for the purposes of controlled release and cancer cell targeting. Nanoparticles composed of artificial polymers, proteins, polysaccharides and lipids have been developed for the delivery of therapeutic deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequences to target cancer. In addition, the effectiveness of cancer targeting has been enhanced by surface modification or conjugation with biomolecules on the surface of nanoparticles. In this review article we provide an overview on the latest developments in nanoparticle-based targeted gene therapy for lung cancers. Firstly, we outline the conventional therapies and discuss strategies for targeted gene therapy using nanoparticles. Secondly, we provide the most representative and recent researches in lung cancers including malignant pleural mesothelioma, mainly focusing on the application of Polymeric, Lipid-based, and Metal-based nanoparticles. Finally, we discuss current achievements and future challenges.
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine in The College of Medicine, Malcom Randall VA Medical Center, University of Florida P. O. Box 100225, USA.
Hung-Yen
HY
Lee
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine in The College of Medicine, Malcom Randall VA Medical Center, University of FloridaP. O. Box 100225, USA; North Florida/South Georgia Veterans Health System, Malcom Randall VA Medical Center, University of FloridaP. O. Box 100225, USA.
Kamal A
KA
Mohammed
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine in The College of Medicine, Malcom Randall VA Medical Center, University of FloridaP. O. Box 100225, USA; North Florida/South Georgia Veterans Health System, Malcom Randall VA Medical Center, University of FloridaP. O. Box 100225, USA.
Najmunnisa
N
Nasreen
EphA2; EphrinA1; Lung cancer; malignant mesothelioma; nanoparticles; targeted gene therapy